Neutralizing antibodies against SARS-CoV-2 virus after vaccination in patients with neurofibromatosis type 1
作者机构：Department of Infectious DiseasesNational Medical Center for Infectious DiseasesShanghai Key Laboratory of Infectious Diseases and Biosafety Emergency ResponseHuashan HospitalFudan UniversityShanghaiPeople’s Republic of China Department of Plastic and Reconstructive SurgeryShanghai Ninth People’s HospitalShanghai Jiao Tong University School of MedicineShanghaiPeople’s Republic of China Shanghai Huashen Institute of Microbes and InfectionsShanghaiPeople’s Republic of China
出 版 物：《Signal Transduction and Targeted Therapy》 (信号转导与靶向治疗（英文）)
年 卷 期：2023年第8卷第7期
页 面：3215-3217页
核心收录：
学科分类：0710[理学-生物学] 1001[医学-基础医学(可授医学、理学学位)] 100103[医学-病原生物学] 10[医学]
基 金：This study was supported by grants from the National Natural Science Foundation of China(82202470,82102344,82172228) the Shanghai Rising Star Program supported by the Science and Technology Commission of Shanghai Municipality(20QA1405600) the Natural Science Foundation of Shanghai(22ZR1422300 Innovative research team of high-level local universities in Shanghai(SHSMUZDCX20210400) Clinical Research Plan of SHDC(SHDC2020CR1019B) Shanghai Clinical Research Center of Plastic and Reconstructive Surgery supported by Science and Technology Commission of Shanghai Municipality(Grant No.22MC1940300) Shanghai Municipal Science and Technology Major Project(HS2021SHZX001) Shanghai Science and Technology Committee(21NL2600100,20dz2260100).
主 题：mortality acute respiratory
摘 要：Dear Editor,The severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)has triggered a COVID-19 pandemic that has caused high morbidity and mortality worldwide.1 COVID-19 vaccines are urgently needed to protect all susceptible populations from SARS-CoV-2 infection.Neurofibromatosis type 1(NF1)is a hereditary dominant disease that affects approximately one in every 3000 newborns.
维普期刊数据库